NCT03833245

Brief Summary

The US opioid epidemic continues to result in serious health consequences for pregnant and postpartum women. In the US from 2007 to 2012, an average of 21,000 pregnant women each year reported past month opioid misuse. This study aims to provide rapid and targeted primary prevention activities aimed at assisting pregnant women with opioid use disorder (OUD) to become linked to and retained in treatment in order to reduce harms to them (including overdose) and their offspring.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
102

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 28, 2019

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 6, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

March 11, 2019

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2022

Completed
2.3 years until next milestone

Results Posted

Study results publicly available

February 3, 2025

Completed
Last Updated

February 3, 2025

Status Verified

January 1, 2025

Enrollment Period

3.6 years

First QC Date

January 28, 2019

Results QC Date

December 7, 2023

Last Update Submit

January 27, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Opioid Use Disorder (OUD) and Other Substance Use Disorder (SUD) Treatment Linkage/Retention

    Percentage of days of days of attending outpatient and inpatient Substance Use Disorder treatment.

    6 months

  • Adherence to Medication-Assisted Treatment (MAT) Medication Use Section

    Adherence to MAT will be assessed through the treatment services review (TSR-6) medication use section defined by percentage days of attendance.

    6 months

Secondary Outcomes (1)

  • Adequacy of Prenatal Care

    1 week

Study Arms (2)

Control

NO INTERVENTION

The standard care condition includes brief case management and referral. The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services. All patients will be referred to MAT and any identified behavioral health or social service needs.

Patient Navigation

EXPERIMENTAL

The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.

Behavioral: Patient Navigation

Interventions

The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.

Patient Navigation

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (≥18 years)
  • English speaking
  • Pregnant women (pregnancy status verified by gestational age \>6 weeks from last menstrual period confirmed by ultrasound)
  • OUD verified by examination of medical records for an OUD diagnosis, urine toxicology, and the Diagnostic and Statistical Manual of Mental Disorders (DSM) Checklist (modified from the DSM-IV to confirm current diagnosis for substance use disorders)
  • Plan to carry their babies to delivery verified by patient self report

You may not qualify if:

  • Experienced a psychotic or a manic episode in the last 30 days documented in their medical record
  • Beyond the 25th week of gestation
  • Cannot provide collateral contact information of 2 persons,
  • Cannot provide a reliable phone number,
  • Plan to move from the area within 2 months of their delivery will or 6 months after not be included in the study
  • Inability or unwillingness of subject or legal guardian/representative to give written informed consent.
  • Other factors that would cause harm or increased risk to the participant or close contacts, or preclude the participant's full adherence with or completion of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Magee Women's Hospital

Pittsburgh, Pennsylvania, 15213, United States

Location

University of Utah

Salt Lake City, Utah, 84108, United States

Location

Related Publications (4)

  • Cochran G, Smid MC, Krans EE, Yu Z, Carlston K, White A, Abdulla W, Baylis J, Charron E, Okifugi A, Gordon AJ, Lundahl B, Silipigni J, Seliski N, Haaland B, Tarter R. Patient navigation for pregnant individuals with opioid use disorder: Results of a randomized multi-site pilot trial. Addiction. 2024 Mar;119(3):544-556. doi: 10.1111/add.16364. Epub 2023 Oct 20.

  • Charles JE, Baylis J, Smid MC, Cochran G. Nonfatal Overdoses Among Pregnant Individuals With Opioid Use Disorder. Obstet Gynecol. 2023 May 1;141(5):961-963. doi: 10.1097/AOG.0000000000005129. Epub 2023 Apr 5.

  • Bryan MA, Mallik D, Cochran G, Lundahl B. Mindfulness and Savoring: A Commentary on Savoring Strategies and Their Implications for Addiction Treatment. Subst Use Misuse. 2022;57(5):822-826. doi: 10.1080/10826084.2022.2046090. Epub 2022 Mar 10.

  • Cochran G, Smid MC, Krans EE, Bryan MA, Gordon AJ, Lundahl B, Silipigni J, Haaland B, Tarter R. A pilot multisite study of patient navigation for pregnant women with opioid use disorder. Contemp Clin Trials. 2019 Dec;87:105888. doi: 10.1016/j.cct.2019.105888. Epub 2019 Nov 12.

MeSH Terms

Conditions

Opioid-Related Disorders

Interventions

Patient Navigation

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Patient-Centered CarePrimary Health CareComprehensive Health CarePatient Care ManagementHealth Services Administration

Results Point of Contact

Title
Gerald Cochran, PhD
Organization
University of Utah

Study Officials

  • Gerald Cochran, PhD

    University of Utah

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 28, 2019

First Posted

February 6, 2019

Study Start

March 11, 2019

Primary Completion

October 1, 2022

Study Completion

October 1, 2022

Last Updated

February 3, 2025

Results First Posted

February 3, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations